Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome

Table 3

Clinical outcomes in both study arms.

Clinical outcomes	Magmaris patients N-193	Ultimaster patients N-169	value
30-day FU primary outcome (cardiac death, myocardial infarction, in-stent thrombosis)	0 (0%)	2 (1%)	0.217
30-day FU principal secondary outcome target lesion failure (cardiac death, target vessel myocardial infarction, and need for target lesion revascularization)	0 (0%)	0 (0%)	1
30-day FU death
Any	0 (0%)	0 (0%)	1
Cardiac	0 (0%)	0 (0%)	1
30-day FU myocardial infarction:
Any other	0 (0%)	2 (1%)	0.217
Target vessel	0 (0%)	0 (0%)	1
30–day FU scaffold:
Thrombosis	0 (0%)	0 (0%)	1
Restenosis	0 (0%)	0 (0%)	1
30–day FU revascularisation:
Target lesion	0 (0%)	0 (0%)	1
Target vessel	0 (0%)	0 (0%)	1
Any other	0 (0%)	9 (5%)	0.012
1-year FU primary outcome (cardiac death, myocardial infarction, and in-stent thrombosis)	3 (1.5%)	9 (5%)	0.074
1-year FU principal secondary outcome target lesion failure (cardiac death, target vessel myocardial infarction, and target lesion revascularization)	3 (1.5%)	7 (5.4%)	0.199
1-year FU death:
Any	2 (1.0%)	0 (0%)	0.501
Cardiac	0 (0%)	0 (0%)	1
1-year FU myocardial infarction:
Any other	3 (1.5%)	4 (2%)	0.710
Target vessel	2 (1.0%)	5 (3%)	0.259
1-year FU scaffold
Thrombosis	0 (0%)	0 (0%)	1
Restenosis	2 (1.0%)	2 (1%)	1
1-year FU revascularisation:
Target lesion	2 (1.0%)	3 (2%)	0.668
Target vessel	3 (1.5%)	7 (4%)	0.199
Any other	18 (9.3%)	24 (14%)	0.188

Abbreviations: TIA, transient ischemic attack; PCI, percutaneous coronary intervention; FU-follow up.